Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) shares taking aerial root after this announcement

Related Topics

Facebook
Twitter
LinkedIn
WhatsApp

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) shares hiked 32.30%  to reach $8.11 in the pre-market session after the announcement that they have reached a license and supply agreement for exclusive rights to market and sell products in the United States for over-the-counter (OTC) dermatological products.

Crown plans to sell Sonoma’s Microcyn technology dermal sprays and gels targeting itch and pain under Sarna, the #1 Dermatologist Recommended Anti-Itch Brand, with a unique variety of formulations to quickly relieve itch and skin irritations.

The HOCl line of products from Sonoma is clinically proven to reduce burning, itching, and pain in patients suffering from different kinds of dermatoses, including radiation dermatitis and atopic dermatitis. Sonoma will continue to sell prescription drugs, while Crown will offer over-the-counter products.

Leave a Comment

Your email address will not be published.

Latest Posts